Highlights important gaps and predictors in advance care planning for people with parkinsonism—useful for clinical care and service design but of limited direct relevance to therapeutic discovery or mechanistic research.

This work is useful for improving patient engagement, care planning, and trial readiness in clinical settings but provides minimal mechanistic, biomarker, or therapeutic-discovery information for Parkinson's drug development.

Mechanistically relevant pathways (NMDA signaling, synaptogenesis, neuroinflammation) could make ketamine a candidate for repurposing to treat cognitive symptoms in Parkinson’s, but the paucity of human data and safety/efficacy concerns limit immediate translational value and require controlled…

By pointing to a potentially druggable receptor (FAM171A2) and to structural epitope-targeting strategies that could reduce α‑synuclein spread, the work provides concrete, translatable therapeutic leads for slowing Parkinson’s disease progression.

Highlights shared, targetable pathways (Wnt/β-catenin suppression, impaired structural/axon growth, TRAIL-mediated apoptosis) across hereditary PD forms that generate actionable hypotheses for neuroprotective interventions and biomarker development, though findings are limited to in vitro iPSC…

Provides human-relevant, temporally resolved evidence linking impaired autophagy to α‑synuclein pathology and neuronal loss, supporting autophagy/lysosomal pathways as actionable targets and these organoid models for therapeutic screening.

Shows that alpha-synuclein SAA stratification identifies a biologically relevant subgroup and indicates S+ LRRK2-PD progresses similarly to S+ sporadic PD, informing biomarker-driven trial design, patient selection, and outcome measures for LRRK2- or alpha-synuclein-targeted therapeutics.

The study supports symptomatic repurposing of apomorphine for selected MSA patients—useful for clinical management and designing symptomatic treatment trials—but provides limited mechanistic or disease‑modifying insight relevant to Parkinson's therapeutic discovery.

Provides human physiological evidence linking reward history to dopaminergic signaling and behavioral vigor, offering a potential biomarker of residual DA function and a rationale for tailoring neuromodulation or behavioral interventions in PD.

Provides practical, sustainable assays for routine quality control and manufacturing of entacapone-containing products but offers little mechanistic, translational, or therapeutic-discovery insight for Parkinson's disease research.

Identifies circulating VGF-derived peptides as potential early, disease-specific biomarkers linked to alpha-synuclein pathology with translational value for PD diagnosis or trials, though human validation and mechanistic/therapeutic follow-up are needed.

By directly linking α-synuclein overexpression to spatially resolved alterations in sphingolipid and phospholipid metabolism (including lipid oxidation and ganglioside/sulfatide changes), the work highlights actionable lipid pathways and potential biomarkers that could be targeted or monitored in…

By linking oxidative stress to impaired axonal transport via direct damage to a kinesin motor, the work provides a mechanistic, targetable connection between redox pathology and neurodegeneration that could motivate redox-modulating or motor-stabilizing therapeutic strategies for Parkinson's…

This tool enables longitudinal, in vivo visualization of a metabolic/pathology biomarker (lipid droplets) in the substantia nigra, facilitating biomarker development, mechanistic study of lipid-related PD pathology, and screening of interventions that target lipid metabolism or downstream…

By revealing sex-biased molecular responses to a mitochondrial toxin (rotenone), the work highlights candidate pathways/biomarkers and underscores the importance of sex as a variable for translational biomarker discovery and sex-aware therapeutic strategies in PD research.

By identifying isoform-dependent interfaces and predicted allosteric modulation within D2R/GHSR1a heteromers, the study provides a mechanistic framework that could be exploited to design heteromer- or isoform-selective therapeutics for Parkinson's disease, though experimental validation is required.

It shows peripheral monocyte GCase reflects GBA1 genotype but is unlikely to be a useful peripheral biomarker of cognitive decline or central cholinergic dysfunction, steering therapeutic biomarker efforts toward central measures or alternative targets for GCase-modulating interventions.

NOS offers a practical, scalable olfactory screening method to identify prodromal PD and enrich cohorts for early‑intervention trials and biomarker studies, aiding translational research and trial recruitment even though it does not report new mechanistic or therapeutic interventions.

It highlights glial circadian regulation of neuroinflammation, oxidative stress, and sleep-related processes that are relevant to Parkinson's therapeutic timing and glia-targeted strategies, but remains a broad review with limited direct, actionable targets for immediate drug discovery.

Relevant to Parkinson's for its focus on improving graft survival, modulating neuroinflammation/oxidative stress, and enabling organoid-based cell-replacement or disease-modeling approaches, but it is a conceptual review with limited actionable molecular targets or immediate therapeutic leads.

It highlights misregulated neuronal microexon splicing as a disease mechanism that could be targeted by splice-modulating therapies and may reveal mechanistic convergence across genetic movement disorders, though it has limited direct relevance to canonical Parkinson's disease pathways like…

Although it offers little mechanistic insight for Parkinson's drug discovery, the study reinforces the clinical efficacy of GPi neuromodulation in severe genetic dystonia and supports the translational relevance of basal ganglia DBS approaches across movement disorders.

While offering little in terms of PD-targeted mechanisms or therapeutic discovery, the study is clinically relevant because reduced antipsychotic use in patients with parkinsonism and the high psychotropic burden in DSD underscore medication-safety and symptom-management issues—and the need to…

This identifies a repurposing-ready compound that targets a mechanistically novel, upstream process (biomolecular condensation/LLPS) to prevent α‑syn aggregation, giving a tangible translational lead for PD therapy development pending in vivo efficacy and safety studies.

The study provides objective evidence that multidisciplinary in‑patient care improves motor outcomes and supports using instrumental measures for monitoring and payer justification, but it offers limited mechanistic insight or direct leads for therapeutic discovery.